Novo Nordisk

Novo faces shareholder suit over insulin sales disclosures
Novo faces shareholder suit over insulin sales disclosures
Biopharma Dive
Novo Nordisk
insulin
investors
Flag link:
Novo Nordisk's new diabetes, obesity drugs lift sales outlook
Novo Nordisk's new diabetes, obesity drugs lift sales outlook
Yahoo/Reuters
Novo Nordisk
earnings
Flag link:
Novo extends R&D alliance with AI specialist e-Therapeutics
Novo extends R&D alliance with AI specialist e-Therapeutics
Pharmaforum
Novo Nordisk
R&D
e-therapeutics
artificial intelligence
Flag link:
Novo, e-therapeutics extend Type 2 diabetes research pact to include new genomics tech
Novo, e-therapeutics extend Type 2 diabetes research pact to include new genomics tech
Fierce Biotech
Novo Nordisk
e-therapeutics
drug discovery
type 2 diabetes
Flag link:
New York investigating 3 insulin makers' pricing strategies
New York investigating 3 insulin makers' pricing strategies
Beckers Hospital Review
New York
insulin
diabetes
Sanofi
Eli Lilly
Novo Nordisk
Flag link:
Roche and Novo Nordisk Top Clinical Trial Transparency Survey
Roche and Novo Nordisk Top Clinical Trial Transparency Survey
BioSpace
Roche
Novo Nordisk
JNJ
clinical trials
clinical trial transparency
Flag link:
Score! 'Good Pharma' ranking finds uptick in new drug data sharing and clinical trial transparency
Score! 'Good Pharma' ranking finds uptick in new drug data sharing and clinical trial transparency
Fierce Pharma
pharma industry
Good Pharma
Novo Nordisk
Roche
clinical trial transparency
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
Yahoo/Benzinga
Retrophin
Karyopharm
Celyad
uniQure
Sangamo Therapeutics
Catalyst Biosciences
Novo Nordisk
Reata Pharmaceuticals
Vertex Pharmaceuticals
Bellicum
Gilead Sciences
Jaguar Health
TRACON Pharmaceuticals
FibroGen
Aslan Pharma
ObsEva
Sorrento Therapeutics
Flag link:
Novo Nordisk’s Victoza gets FDA okay for pediatric use
Novo Nordisk’s Victoza gets FDA okay for pediatric use
Pharmaforum
Novo Nordisk
Victoza
type 2 diabetes
pediatric
Flag link:
Novo Nordisk goes for broke on semaglutide heart data
Novo Nordisk goes for broke on semaglutide heart data
Biopharma Dive
Novo Nordisk
diabetes
FDA
Ozempic
oral semaglutide
Flag link:
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Fierce Pharma
Eli Lilly
ADA
diabetes
heart attack
stroke
Trulicity
Novo Nordisk
semaglutide
Flag link:
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney disease
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney disease
Pharmaforum
Novo Nordisk
type 2 diabetes
diabetes
chronic kidney disease
Flag link:
Novo Nordisk Trots Along Waiting for Its Next-Generation Oral Drug
Novo Nordisk Trots Along Waiting for Its Next-Generation Oral Drug
Motley Fool
Novo Nordisk
earnings
diabetes
oral semaglutide
FDA
Flag link:
Renewable Energy Will Power all of Novo Nordisk’s Production Facilities by 2020
Renewable Energy Will Power all of Novo Nordisk’s Production Facilities by 2020
BioSpace
Novo Nordisk
drug manufacturing
renewable energy
environmental concerns
Flag link:
Novo seeks Victoza label expansion with fresh pediatric trial results
Novo seeks Victoza label expansion with fresh pediatric trial results
Biopharma Dive
Novo Nordisk
type 2 diabetes
pediatrics
Victoza
Flag link:
Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs
Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs
TheStreet.com
NASH
Gilead Sciences
Novo Nordisk
clinical trials
Flag link:
Novo Nordisk seeks FDA nod for oral diabetes pill
Novo Nordisk seeks FDA nod for oral diabetes pill
Drug Delivery Business News
Novo Nordisk
FDA
semaglutide
diabetes
Flag link:
Novo Nordisk settles US patent litigation case on Victoza (liraglutide) with Teva
Novo Nordisk settles US patent litigation case on Victoza (liraglutide) with Teva
Pharmaceutical Business Review
Novo Nordisk
Teva Pharmaceutical
patents
Victoza
diabetes
Flag link:
Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?
Fierce Pharma
Novo Nordisk
diabetes
Teva Pharmaceutical
Victoza
semaglutide
Flag link:
Novo Nordisk Launches Innovation Platform in China
Novo Nordisk Launches Innovation Platform in China
CP Wire
Novo Nordisk
China
innovation
Innovo
Flag link:

Pages